Express Scripts Inc.  (ESRX) Trade Now »     Rate ESRX  -  Discuss ESRX  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

ESRX: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Bullish on ESRX ... ESRX

62%

+94.50% in 225 days Express Scripts, Inc. offers a range of pharmacy benefit management (PBM) services in North America. The company provides retail network pharmacy management, retail drug card programs, home delivery pharmacy services, benefit design consultation, drug utilization review, drug formulary management programs, and compliance and therapy management programs. It also offers integrated PBM services that comprise network claims processing, home delivery services, benefit design consultation, drug utilization review, formulary management, and drug data analysis services. In addition, Express Scripts... Continue reading »

Health Benefit Providers Index Drops on Reform Prospects ESRX

73%

+68.16% in 254 days The accompanying table includes 38 companies in the ETF Innovators Health Benefit Providers Index, which was down sharply in the past week and has lost 14% of its market value to a level of 192,305 since I last wrote about the group five weeks ago. <> <> The uncertain future for health insurers and benefit providers that I wrote about previously came to a head this week with plans by President Obama for healthcare reform aimed at cutting health costs by favoring generic drug makers and smaller Medicare Advantage payments to private insurers, along with smaller increases... Continue reading »

Healthcare Investing Trends in '09 and Beyond ESRX

73%

-14.29% in 21 days (closed on 02/28/09) Healthcare Investing Trends for '09 and Beyond <> While the departure of Tom Daschle and concerns over rising unemployment and the global economic slowdown may hamper many of President Obama's plans for healthcare reform; there are several growth trends within the sector outlined below which are poised to benefit in 2009 and beyond. Follow any of the links below for more information on the new ETF Innovators indexes and exchange-traded fund ideas for the sector. Global Health IT : The top five rated companies include Swiss telemedicine firm Card Guard (CDGUF) – a pro< />< />< />< /><>< />< />< />< /><><>< />< /><>< />< />< />< /><>... Continue reading »

Health Cost Containment Index: Expanded into India, Impax Labs to Re-List ESRX

73%

+2.52% in 71 days (closed on 02/07/09) Health Cost Containment Index: Expanding into India, Impax Labs Set to Re-List <> The ETF Innovators [ETFI] Global Healthcare Cost Containment Index profiled in the accompanying table is updated and expanded to include more companies from my recent Analysis of Generic Drug Companies from India . The index is structured to include companies with market caps between $150M-$60B, which are involved in producing generic healthcare products such as generic drugs and pharmacy benefit managers which do not have retail store and insurance components. The Top 10 ... Continue reading »

A New Global Healthcare Composite Index ESRX

73%

+4.42% in 4 days (closed on 11/27/08) A New Global Healthcare Composite Index <> The accompanying table [click to enlarge or download] presents the top five rated companies with market caps of at least $250M from each of the 10 new healthcare indexes developed by ETF Innovators [ETFI] from a database of about 500 companies worldwide. The ETFI Global Healthcare Sector PerformIdex consists of 50 top rated companies on an equal weight basis from each of the 10 new healthcare indexes as an alternative strategy to existing health composite ETFs with highly correlated returns and over-weight exposure to th... Continue reading »

From the Blogosphere

Consider Express Scripts, unless you think health care reform will lead to fewer Americans with insurance

Filed under: Stocks to Buy I'm Reiterating my Buy rating for Express Scripts (NASDAQ: ESRX), first recommended on June 9, 2009 at a price of $63.64, and the reason isn't the stuff of rocket science. An aging populace, plus a likely renewed emphasis on health and wellness in the United States, and the probability of federal health care reform legislation bodes well for many health care players, including pharmacy benefits managers like ESRX. If you bought the shares on June 9, you're up about 20%.<><>Continue reading <>Consider Express Scripts, unless you think health care reform will lead to fewer... Continue reading »

Cramer on BloggingStocks: China-led drop offers a time to buy ESRX

+25.77% in 82 days Filed under: Apple Inc (AAPL), Ford Motor (F), Exxon Mobil (XOM), China, Market matters, Citigroup Inc. (C), Target Corp. (TGT), BB and T (BBT), Bristol-Myers Squibb (BMY), Wendy's Intl (WEN), BHP Billiton Ltd ADR (BHP), Freep't McMoRan Copper (FCX), Stocks to Buy, Union Pacific Corporation (UNP), Cramer on BloggingStocks, Potash Corp. of Saskatchewan (POT) From TheStreet.com Network Here We Go Again? Asian Markets Plunge Is the Pullback Over?: Dow Watch TheStreet.com's Jim Cramer says even stocks without exposure to that country will probably be on sale today. If China has... Continue reading »

Cramer on BloggingStocks: You can't afford to be certain ESRX

-6.83% in 19 days (closed on 08/19/09) <>Filed under: Apple Inc (AAPL), Hewlett-Packard (HPQ), Ford Motor (F), Market matters, Walt Disney (DIS), International Business Machines (IBM), AT and T (T), 3M Corporation (MMM), Caterpillar (CAT), Schlumberger Limited (SLB), Citigroup Inc. (C), Johnson and Johnson (JNJ), JPMorgan Chase (JPM), Bank of America (BAC), Bed Bath and Beyond (BBBY), Best Buy (BBY), FedEx Corp (FDX), Verizon Communications (VZ), Lennar Corp'A' (LEN), United Parcel'B' (UPS), Anadarko Petroleum (APC), Wells Fargo (WFC), Stocks to Buy, Norfolk Southern Corp. (NSC), Union Pacific Corporation (UNP), <>Cramer on Blogging... Continue reading »

Cramer on BloggingStocks: The health care bargain ESRX

+2.11% in 4 days (closed on 07/31/09) Filed under: Pfizer (PFE), Market matters, Johnson and Johnson (JNJ), Abbott Laboratories (ABT), Bristol-Myers Squibb (BMY), Merck and Co (MRK), Stocks to Buy, Cramer on BloggingStocks From TheStreet.com Network Coming Week: More Earnings, Upside Higher Medical Costs Crimp Aetna Profits TheStreet.com's Jim Cramer says health care has never been this cheap relative to the market in its history. Health care's not done rallying. As President Obama prepared himself for claiming a great political victory, we are all recognizing that the single-payer, socialized medicine coverin... Continue reading »

October 9th - filter results

25%

Hi, One of my stocks sold out nicely today (ESRX) for a 6% profit. CTV is really struggling and I am more than a little frustrated with it as it may continue to under-perform. Once it covers my costs - I am out! I am away for the next three days so I will be back bloggin' next Monday... Todays filter results: M1 : ITU** KMGB M2: DADE M3: VSEA WHQ** KMGB performed badly today - 10% drop. It will be interesting to see what happens tomorrow. BCSI (one of my picks from last week) did amazingly well - I think it is up 10+%. Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.